miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options. Here, we pursued a combinatorial therapeutic approach to enhance the activity of selinexor, the first-in-class XPO1 inhibitor, by miR-34a ectopic expression in human TNBC experimental models. Anti-prolife...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pharmaceuticals (Basel)
Autors principals: Martini, Silvia, Zuco, Valentina, Tortoreto, Monica, Percio, Stefano, Campi, Elisa, El Bezawy, Rihan, Doldi, Valentina, Landesman, Yosef, Pennati, Marzia, Zaffaroni, Nadia
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8227962/
https://ncbi.nlm.nih.gov/pubmed/34072442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14060523
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars